Brought to you by:
WVS 2021: Western Vascular Society names new president-elect
University of Southern California (USC) vascular chief Vincent Rowe, MD, took over as the new president of the Western Vascular Society (WVS)—with University of Arizona chief of vascular surgery Wei Zhou, MD, named the new president-elect—during the organization’s 2021 annual…
The top 10 most popular Vascular Specialist stories in September
Five-year data from the ACST-2 trial comparing carotid endarterectomy and carotid artery stenting, a report from the Crawford Forum at the 2021 Vascular Annual Meeting (VAM), and an Eastern Vascular Society (EVS) annual meeting piece reporting on vascular surgery as…
PROMISE I 24-month results ‘validate the benefits of the LimFlow system’
LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for both amputation-free survival and wound healing, a press release reports. The late-breaking data were presented at…
One-year results show ‘superior’ primary patency rate for Eluvia DES compared to bare metal stents
One-year results presented at Vascular Interventional Advances (VIVA) 2021 in Las Vegas (Oct. 5–7) from the EMINENT trial demonstrated the superiority of the Eluvia drug-eluting stent (DES) system (Boston Scientific) compared to self-expanding bare metal stents for the treatment of…
VIVA 2021: IVL ‘consistently’ treats real-world calcium in multiple peripheral vessel beds
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL) performs “consistently well” across challenging peripheral vessels, lesions and subgroups of patients, Ehrin J. Armstrong, MD, medical director at Adventist Heart and Vascular Institute in…
Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy
Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results from the RANGER II SFA randomized controlled trial have demonstrated, investigators revealed during a late-breaking session…
VIVA 2021: Consensus established for appropriate use of IVUS in peripheral interventions
A worldwide committee of 40 cross-specialty medical experts achieved what was hailed as the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions. Global experts conducted a systematic and comprehensive review of key…
Save the date for new PAD skills workshop
September is National PAD Awareness Month, and the Society for Vascular Surgery (SVS) will spend the month not only calling attention to causes and treatment for the disease, but also planning a peripheral arterial disease (PAD) skills workshop. The hands-on…
First patient enrolled in BIONETIC-I study of iliac artery treatment
Biotronik has announced the first patient enrollment in the BIONETIC-I study of the safety and efficacy of the Dynetic-35 cobalt chromium balloon-expandable stent system for the treatment of atherosclerotic peripheral arterial disease (PAD) lesions in the iliac arteries. The study…
‘Proceed cautiously in use of DCBs in CLTI patients with advanced WIfI stage’
The last several years have seen ongoing controversy and debate about the risks and benefits of paclitaxel-coated devices (PCDs) for patients with peripheral arterial disease (PAD). The latest contribution from Konstantinos Katsanos, MD, and colleagues raises questions about potential increased…